We can’t show the full text here under this license.
Abstract
Semaglutide is associated with significant reductions in major adverse cardiovascular events (MACE) for patients with obesity and diabetes.
- Improvements in heart failure symptoms and exercise capacity have been observed with Semaglutide treatment.
- A notable reduction in NT-proBNP levels indicates potential benefits for heart failure management.
- Semaglutide may decrease inflammation by lowering C-reactive protein and tumor necrosis factor-alpha levels.
- The SELECT trial suggests cardiovascular benefits of Semaglutide extend to non-diabetic, obese patients.
- These findings could represent a shift in approaches to cardiovascular risk management.
Simplified